

Hot topics / In the News March



12th March 1pm-2pm NIHR Webinar

Presentations will be followed by Q&A
Presenters:

- Archana Gopalakrishnan, Clinical Research Fellow (Urology), Imperial College London
- Richard Bryant, Associate Professor and Consultant Urologist, University of Oxford
- Krishna Narahari, Professor and Consultant Urologist, University Hospital of Wales, Cardiff

https://gmglcggroup.zoom.us/webinar/register/5217379728807/WN_HNqyhR0sTBGCGMyv716gEw#/registration



National Institute for Health and Care Research ✓
@NIHRresearch



Prostate cancer is the most common cancer in men, with over 55,000 new cases each year in the UK. Join us to explore ongoing NIHR trials shaping the future of treatment for localised prostate cancer 💡



Register here: [gmglcggroup.zoom.us/webinar/register...](https://gmglcggroup.zoom.us/webinar/register/5217379728807/WN_HNqyhR0sTBGCGMyv716gEw#/registration)

@ProstateUK @PCFnews @PCR_News

NIHR | National Institute for Health and Care Research

WEBINAR

What's next for prostate cancer research?

12 March
1pm - 2pm

ALT



SIR CHRIS HOY'S 2025 TOUR DE 4 TO LAUNCH IN SCOTLAND

London, 5 February 2025: Sir Chris Hoy has today announced that the inaugural Tour de 4 will take place in Scotland on Sunday 7th September 2025. Beginning and finishing at the Sir Chris Hoy velodrome in Glasgow, this brand new fundraising charity ride aims to help change the perception of people living with stage 4 cancer, whilst also raising vital funds for cancer charities across the UK

<https://www.tourde4.com>



“Figures shared with the BBC show:

- 30% of patients with high-risk prostate cancer do not get curative treatment with either surgery or radiotherapy, with performance varying between 20% and 43% across different services”

Cancer patients not getting right treatment, say doctors

B B C

NEWS



GETTY IMAGES

Nick Trigg >

Health correspondent

@nicktrigg >

<https://www.bbc.co.uk/news/articles/c86pl3962j7o>



<https://www.bbc.co.uk/news/articles/cj0q228ry5yo>



PMQs 26th Feb 2025

https://x.com/PCR_News/status/1894736099844481082



ProstateCancerResearch ✓
@PCR_News



A major moment for prostate cancer screening at PMQs today. [@RishiSunak](#) highlighted the urgent need for action and referenced the vital work of Prostate Cancer Research. We're delighted [@Keir_Starmer](#) was so supportive!

Join us and let's make this a reality: mailchi.mp/pcr.org.uk/pro...




OXFORD
ACADEMIC

Journals

Books

i

 JOURNAL of the
NATIONAL CANCER INSTITUTE

Issues

More Content ▼

Submit ▼

Purchase

Alerts

About ▼

JNCI: Journal of the Nation ▼

NEW: We have upgraded our email alerts. You can sign up using the 'Email alerts' panel available on most pages, or in your Oxford Academic personal account.

Article Contents

Abstract

Introduction

Methods

Results


Discussion


Acknowledgments

Author contributions

JOURNAL ARTICLE

CORRECTED PROOF

Incidence and prognostic implications of prostate-specific antigen persistence and relapse after radical prostatectomy: population-based study 

Pietro Scilipoti, MD, Hans Garmo, PhD, Rolf Gedeberg, MD, PhD,
David Robinson, MD, PhD, Pär Stattin, MD, PhD, Marcus Westerberg, PhD 

JNCI: Journal of the National Cancer Institute, djaf012,
<https://doi.org/10.1093/jnci/djaf012>

Published: 17 January 2025 **Article history ▼**

<https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf012/7959533?login=false>

Abstract

Background: There has been a wide range in incidence of prostate-specific antigen (PSA) persistence and relapse after radical prostatectomy (RP) for prostate cancer (PCa). We aimed to describe incidence and prognostic implications of PSA persistence and relapse.

Methods: Register-based cohort study in Sweden of men diagnosed with PCa between 2007 and 2020 who underwent RP. Risks were estimated using competing risk cumulative incidence curves. Treatment after persistence or relapse and risk of PCa death and other causes were stratified according to persistence, European Association of Urology relapse risk groups, time to relapse, and life expectancy based on age and comorbidities.

Results: Among 10 700 men, the 10-year risk of PSA persistence or relapse after RP was 34% (95% confidence interval = 32% to 35%). Within 12 months of persistence/relapse, 75% of men with persistence, high-risk relapse, or early relapse (<2 years) received treatment. The 10-year risk of PCa death ranged from 12% for men with persistence to 2% in men with low-risk relapse, whereas death from other causes ranged from 11% to 16%. Risk of PCa death was 8.5% after early relapse (<2 years) and 1.4% after late relapse (>5 years).

Conclusions: This population-based study estimated that one-third of men would have PSA persistence or relapse within 10 years from RP. There was a wide range in risk of death from PCa according to cancer characteristics and time to relapse. Risk of death from other causes was substantial. These factors, along with life expectancy, should inform treatment decisions for men with persistence or relapse.



£220K AWARDED

(CO-FUNDED BY PROSTATE CANCER UK)
TO TACKLE PROSTATE CANCER



Men in deprived areas often struggle to access information about prostate cancer treatments and side effects, leading to uncertainty and even regret after treatment. This grant will pilot a peer coaching service, connecting men with others who've been through it, to help them and their caregivers make informed treatment decisions.

<https://x.com/MovemberUK/status/1886776939320373269>

Movember Peer Coaching Pilot

Why This Matters

- Prostate cancer is the most common cancer in men, with **58,000+ diagnoses annually** in the UK.
- Many people struggle with **treatment decisions** due to limited access to **clear, tailored information**.
- **Peer coaching** helps newly diagnosed **navigate options, reduce regret, and improve well-being**.

Key Value of the Pilot

- **Enhancing Support Networks:** Connecting those newly diagnosed with **trained peer coaches**.
- **Reducing Treatment Regret:** Helping people **explore informed choices** to avoid post-treatment regret.
- **Targeting Health Inequalities:** Focused outreach in **underrepresented and deprived communities**. - North, Midlands and across LGBTQ+ community
- **Driving Awareness & Engagement:** Expanding **referral pathways** through clinical teams, workplaces, and charities.

National PC Partner Support Group,

on Zoom. (Partners only, not patients.)

Supporting partners of those diagnosed with Prostate Cancer. Partners should email Janet Daykin and Caroline if they wish to attend.

janetldaykin@gmail.com carolineopcs@gmail.com



Monday 17th March

Tuesday 29th April


Monday 16th June

Tuesday 22nd July

Monday 15th September

Tuesday 28th October

Monday 15th December



6.30pm start with room
opening at 6.10pm


Living Well with Advanced Prostate Cancer Virtual Support Group

For those diagnosed with Advanced Prostate Cancer.
Please email aidan.adkins@tackleprostate.org if you
wish to attend.



- Monday 24th March (4th Monday)
- Monday 28th April
- Monday 26th May

6.00pm start



**Living Well
with
Advanced
Prostate
Cancer**
Virtual Support Group

Monthly Zoom Meeting

Last Monday of every month
6-7.30pm

Contact for more details:
aidan.adkins@tackleprostate.org
www.tackleprostate.org

- Diagnosed with Advanced Prostate Cancer?
- Has your Prostate Cancer returned?
- You are not alone. Join others who are in the same boat

#TogetherWeTackle

tackle
prostate cancer

BUPA Counselling through Macmillan



No longer available

FREE SPECIALIST COUNSELLING

Through Bupa, Macmillan are offering up to six counselling sessions, free for people struggling emotionally because of cancer. Within days, people who are eligible can receive specialist, remote support.

<https://www.macmillan.org.uk/cancer-information-and-support/get-help/emotional-help/bupa-counselling-and-emotional-well-being-support>